IMV Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific & Clinical Advisors
    • Partnerships
  • The DPX Platform
    • Overview
    • Scientific Publications & Posters
  • Clinical Pipeline
    • Overview
    • DPX-Survivac
    • DPX-RSV
    • DPX-COVID-19
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • Email Alerts
  • Investors
    • Overview
    • Press Releases
    • Events, Webcasts & Presentations
    • Financial Info
    • Stock Data
    • Filings
    • Governance
    • Contact Us
    • FAQ
  • Careers
    • Overview
    • Life at IMV
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events, Webcasts & Presentations
    • Overview
    • Presentations
    • Scientific Publications & Posters
    • Email Alerts
  • Financial Info
    • Financial Results
    • Tax Info
    • Proxy Info
    • Stock Option Plan
    • Deferred Share Unit Plan
  • Stock Data
    • NASDAQ: IMV
    • TSX: IMV
    • Analyst Coverage
  • Filings
    • SEC Filings
    • SEDAR
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact Us
  • FAQ
Jul 20, 2020 7:05am EDT

IMV Announces Appointment of Michael P. Bailey to Board of Directors

Jul 14, 2020 7:05am EDT

IMV Updates Rapid Progress on COVID-19 Vaccine Program

Jun 30, 2020 5:05pm EDT

IMV maintains the remainder of its At-the-Market Facility under its new Base Shelf Prospectus

Jun 29, 2020 5:05pm EDT

IMV Announces Annual and Special Meeting of Shareholders Voting Results

Jun 19, 2020 4:26pm EDT

IMV Files Preliminary Base Shelf Prospectus to Replace Expiring Base Shelf Prospectus

Jun 15, 2020 7:05am EDT

IMV Announces Leading Independent Proxy Advisory Firms Recommend Shareholders Vote FOR All Resolutions at Upcoming Annual and Special Meeting

Jun 08, 2020 7:05am EDT

IMV to Present at Raymond James' Human Health Innovation Conference

May 29, 2020 8:05am EDT

Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer

May 21, 2020 7:05am EDT

IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies

May 15, 2020 7:05am EDT

IMV Inc. Provides Clinical and Operational Update and Announces First Quarter 2020 Financial Results

RSS
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...35
  • Next
  • Email Alerts
  • Contacts
  • RSS News Feed
IMV Inc.
About Us The DPX Platform Clinical Pipeline News & Events Investors Careers Contact
Twitter LinkedIn Youtube
© 2021 IMV Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap